---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-000780"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:01:21.303166+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology presents onvansertib data: 73% DCR in 2L KRAS-mut mCRC; FDA Type C meeting supports accelerated path

## Summary
- 73% disease control rate in 2L KRAS-mutated mCRC; median overall survival 15 months vs ~8 months historical.
- FDA Type C meeting (June 2023) agreed on mCRC development plan supporting potential accelerated approval.
- Topline data from 1st-line RAS-mutated mCRC trial expected mid-2024.
- Cash runway extends into 2025; collaboration with Pfizer under Pfizer Ignite program.
- Preclinical data show onvansertib + bevacizumab reduces tumor size and vascularization in KRAS G12V model.

## SEC filing metadata
- accession: 0001628280-24-000780
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828024000780/0001628280-24-000780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828024000780/crdf-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-000780
- JSON: https://secwatch.observer/filing/0001628280-24-000780.json
- Plain text: https://secwatch.observer/filing/0001628280-24-000780.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.